Tepezza

Closeup of blue eye on black background
Biotech

Viridian’s Tepezza rival scores ph. 3 win, but investors unsure

Despite the primary endpoint hit, the candidate's inability to meet investors’ expectations cast a shadow over the results.
James Waldron Mar 30, 2026 10:11am
eye eyeball eye art

Sling's oral Tepezza rival hits goal in thyroid eye disease

Jan 14, 2025 8:16am
eye eyeball eye art

Viridian eye disease phase 3 hits, advancing push to rival Amgen

Sep 10, 2024 8:10am
Businessman puts his box of his belongs on the desk and holds a white letter

Acelyrin loses interest in izokibep, lays off 3rd of staff

Aug 13, 2024 4:00pm
Two hands gripping onto a rope seemingly tugging in opposite directions

Acelyrin's proof-of-concept TED data cement Amgen challenge

Mar 20, 2024 7:00am